Military Standards for Anaphylaxis: Aligning Allergy Science, Operational Risk, and Waiver Documentation.

purpose of the reviewAllergic disease is common in the United States, and a growing number of otherwise qualified applicants and service members present with histories of food allergy, venom allergy, medication reactions, physical urticarias, or prior anaphylaxis. The challenge for clinicians is to translate a nuanced allergy-immunology evaluation into strict military accession and retention standards designed for readiness, austere care, and deployability, rather than for diagnosis alone. RECENT

findingsThe current accession standard disqualifies a history of anaphylaxis other than to a single medication or medication class; systemic allergic reactions to biting or stinging insects unless limited to a large local reaction or accompanied by documentation of 3 years of maintenance venom immunotherapy; acute allergic reactions to fish, crustaceans, shellfish, peanuts, or tree nuts when food-specific IgE is accompanied by a correlating clinical history; and cold- or exercise-induced urticaria [1]. Retention standards are more functional and focus on recurrent anaphylaxis that persists despite treatment, requires long-term duty limitations, or prevents return to duty [2]. Newer therapeutic options, including oral immunotherapy (OIT) and omalizumab, raise reaction thresholds for selected patients but do not establish unrestricted tolerance.[3, 4] This latter point precludes serving in operational settings. A clinically useful waiver evaluation should differentiate sensitization from clinical allergy. Resolved allergy versus desensitization or sustained unresponsiveness should also be determined. The identification of cofactors that lower reaction thresholds, and specifying whether the individual can safely train, deploy, subsist on field rations, and function without refrigeration-dependent or injectable therapy is imperative. Major gaps remain. These include few military-specific outcome data on allergy waivers, limited validated biomarkers that predict future anaphylaxis severity, and no standardized pathway for cold- or exercise-induced urticaria comparable with the venom immunotherapy exception.